Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biogen Idec and Sobi report haemophilia B drug trial data

Biogen Idec and Sobi report haemophilia B drug trial data

28th September 2012

Biogen Idec and partner Swedish Orphan Biovitrum (Sobi) have published new clinical data that demonstrates the potential benefits of a new haemophilia B therapy.

Results from the phase III trial B-Long have shown that the companies' long-lasting recombinant Factor IX Fc fusion protein was effective in the control and prevention of bleeding, routine prophylaxis and perioperative management of the rare inherited disorder.

The clotting factor candidate will be submitted for US regulatory approval in the first half of 2013, while a European Medicines Agency filing will follow the completion of the accompanying paediatric Kids B-Long study.

It is thought that the application of Fc fusion technology can help to extend the half-life of clotting factors, offering more consistent protection with fewer injections.

Dr Glenn Pierce, senior vice-president of global medical affairs and chief medical officer of Biogen Idec's haemophilia therapeutic area, said: "Currently, prophylactic treatment of haemophilia B requires intravenous injections up to three times a week, which makes the prospect of a longer-lasting Factor IX therapy very exciting."

This comes after Biogen Idec published positive data from a recent trial of the multiple sclerosis treatment BG-12 last week.ADNFCR-8000103-ID-801459183-ADNFCR

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.